SI9520153B - Variante humane DNaze I - Google Patents
Variante humane DNaze I Download PDFInfo
- Publication number
- SI9520153B SI9520153B SI9520153A SI9520153A SI9520153B SI 9520153 B SI9520153 B SI 9520153B SI 9520153 A SI9520153 A SI 9520153A SI 9520153 A SI9520153 A SI 9520153A SI 9520153 B SI9520153 B SI 9520153B
- Authority
- SI
- Slovenia
- Prior art keywords
- human dnase
- amino acid
- actin
- variant
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1 Patentni zahtevki 1. Proti aktinu odporna varianta humane DNaze I, ki ima DNA hidrolitično aktivnost, vezavno afiniteto za aktin, kije manjša od vezavne afinitete za aktin nativne humane DNaze I, in aminokislinsko sekvenco, ki ima vsaj 90 % identičnost z aminokislinsko sekvenco nativne humane DNaze I, prikazane na sl. 1.
2. Proti aktinu odporna varianta humane DNaze I po zahtevku 1, ki obsega aminokislinsko sekvenco, ki ima vsaj 95 % identičnost z aminokislinsko sekvenco nativne humane DNaze I, prikazane na sl. 1.
3. Proti aktinu odporna varianta humane DNaze I po zahtevku 1 ali 2, ki ima vsaj eno aminokislinsko substitucijo za drugo pri enem ali večih naslednjih položajih: His44, Leu45, Val48, Gly49, Leu52, Asp53, Asn56, His64, Tyr65, Val66, Val67, Glu69 ali Alal 14.
4. Proti aktinu odporna varianta humane DNaze I po zahtevku 3, ki ima aminokislinsko substitucijo za drugo pri enem od navedenih položajev.
5. Proti aktinu odporna varianta humane DNaze I po zahtevku 1, ki ima aminokislinsko sekvenco, ki se razlikuje od aminokislinske sekvence, prikazane na sl. 1, z le eno aminokislinsko substitucijo pri enem ali večih izmed naslednjih položajev: His44, Leu45, Val48, Gly49, Leu52, Asp53, Asn56, His64, Tyr65, Val66, Val67, Glu69 ali Alal14. 2
6. Proti aktinu odporna varianta humane DNaze I po kateremkoli od zahtevkov 3-5, kjer aminokislinska substitucija ustvari glikozilacijsko mesto znotraj navedene variante, ki ni prisotno v nativni humani DNazi I.
7. Izolirana nukleinska kislina, ki kodira proti aktinu odporno varianto humane DNaze I po kateremkoli od zahtevkov 1 do 6.
8. Uporaba variante humane DNaze I po kateremkoli od zahtevkov 1 do 6 v izdelavi zdravila za zdravljenje cistične fibroze.
9. Uporaba variante humane DNaze I po kateremkoli od zahtevkov 1 do 6 v izdelavi zdravila za zdravljenje kroničnega bronhitisa.
10. Farmacevtski sestavek, ki obsega varianto humane DNaze I po kateremkoli od zahtevkov 1 - 6 in, po izbiri, farmacevtsko sprejemljiv ekscipient.
11. Sestavek po zahtevku 10, kjer je sestavek v tekoči obliki.
12. Sestavek po zahtevku 10, kjer je sestavek v obliki prahu.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1995/002366 WO1996026278A1 (en) | 1995-02-24 | 1995-02-24 | HUMAN DNase I VARIANTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI9520153A SI9520153A (sl) | 1998-06-30 |
| SI9520153B true SI9520153B (sl) | 2004-10-31 |
Family
ID=22248728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9520153A SI9520153B (sl) | 1995-02-24 | 1995-02-24 | Variante humane DNaze I |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0811068B1 (sl) |
| JP (1) | JPH11505408A (sl) |
| AT (1) | ATE230027T1 (sl) |
| AU (1) | AU720635B2 (sl) |
| BG (1) | BG64061B1 (sl) |
| BR (1) | BR9510323A (sl) |
| CA (1) | CA2210871C (sl) |
| CZ (1) | CZ288633B6 (sl) |
| DE (1) | DE69529235T2 (sl) |
| DK (1) | DK0811068T3 (sl) |
| ES (1) | ES2188653T3 (sl) |
| HU (1) | HU223272B1 (sl) |
| MX (1) | MX9706428A (sl) |
| NO (1) | NO326612B1 (sl) |
| PL (1) | PL180773B1 (sl) |
| PT (1) | PT811068E (sl) |
| RU (1) | RU2215787C2 (sl) |
| SI (1) | SI9520153B (sl) |
| SK (1) | SK283850B6 (sl) |
| UA (2) | UA66749C2 (sl) |
| WO (1) | WO1996026278A1 (sl) |
| ZA (1) | ZA961419B (sl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK284191B6 (sk) * | 1995-02-24 | 2004-10-05 | Genentech, Inc. | Aktín-rezistentný variant humánnej DNázy I |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| EP1433842B1 (en) | 2002-12-18 | 2011-01-05 | Roche Diagnostics GmbH | Recombinant bovine pancreatic desoxyribonuclease I with high specific activity |
| ATE494367T1 (de) | 2002-12-18 | 2011-01-15 | Hoffmann La Roche | Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität |
| WO2013114374A1 (en) * | 2012-02-01 | 2013-08-08 | Protalix Ltd. | Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2130120T3 (es) * | 1988-12-23 | 1999-07-01 | Genentech Inc | Procedimiento para la preparacion de la adnasa humana. |
| US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
-
1995
- 1995-02-24 ES ES95912611T patent/ES2188653T3/es not_active Expired - Lifetime
- 1995-02-24 HU HU9800180A patent/HU223272B1/hu not_active IP Right Cessation
- 1995-02-24 BR BR9510323A patent/BR9510323A/pt not_active IP Right Cessation
- 1995-02-24 SK SK1147-97A patent/SK283850B6/sk not_active IP Right Cessation
- 1995-02-24 CA CA002210871A patent/CA2210871C/en not_active Expired - Fee Related
- 1995-02-24 DE DE69529235T patent/DE69529235T2/de not_active Expired - Lifetime
- 1995-02-24 MX MX9706428A patent/MX9706428A/es not_active IP Right Cessation
- 1995-02-24 UA UA97084355A patent/UA66749C2/xx unknown
- 1995-02-24 DK DK95912611T patent/DK0811068T3/da active
- 1995-02-24 JP JP8525640A patent/JPH11505408A/ja not_active Withdrawn
- 1995-02-24 EP EP95912611A patent/EP0811068B1/en not_active Expired - Lifetime
- 1995-02-24 PT PT95912611T patent/PT811068E/pt unknown
- 1995-02-24 WO PCT/US1995/002366 patent/WO1996026278A1/en active IP Right Grant
- 1995-02-24 AT AT95912611T patent/ATE230027T1/de active
- 1995-02-24 AU AU19703/95A patent/AU720635B2/en not_active Ceased
- 1995-02-24 SI SI9520153A patent/SI9520153B/sl unknown
- 1995-02-24 CZ CZ19972677A patent/CZ288633B6/cs not_active IP Right Cessation
-
1996
- 1996-02-21 UA UA97084356A patent/UA65523C2/uk unknown
- 1996-02-21 RU RU97115780/13A patent/RU2215787C2/ru not_active IP Right Cessation
- 1996-02-22 ZA ZA9601419A patent/ZA961419B/xx unknown
-
1997
- 1997-07-18 PL PL95321890A patent/PL180773B1/pl not_active IP Right Cessation
- 1997-08-21 BG BG101846A patent/BG64061B1/bg unknown
- 1997-08-22 NO NO19973876A patent/NO326612B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ288633B6 (cs) | 2001-08-15 |
| EP0811068A1 (en) | 1997-12-10 |
| SK114797A3 (en) | 1998-02-04 |
| WO1996026278A1 (en) | 1996-08-29 |
| BR9510323A (pt) | 1997-11-11 |
| MX9706428A (es) | 1997-11-29 |
| BG64061B1 (bg) | 2003-11-28 |
| RU2215787C2 (ru) | 2003-11-10 |
| CA2210871A1 (en) | 1996-08-29 |
| JPH11505408A (ja) | 1999-05-21 |
| SI9520153A (sl) | 1998-06-30 |
| NO973876D0 (no) | 1997-08-22 |
| UA65523C2 (en) | 2004-04-15 |
| ATE230027T1 (de) | 2003-01-15 |
| DE69529235D1 (de) | 2003-01-30 |
| SK283850B6 (sk) | 2004-03-02 |
| ES2188653T3 (es) | 2003-07-01 |
| DK0811068T3 (da) | 2003-03-10 |
| ZA961419B (en) | 1997-08-22 |
| PT811068E (pt) | 2003-04-30 |
| PL180773B1 (pl) | 2001-04-30 |
| AU1970395A (en) | 1996-09-11 |
| NO973876L (no) | 1997-10-24 |
| CZ267797A3 (cs) | 1998-01-14 |
| HUT77422A (hu) | 1998-04-28 |
| EP0811068B1 (en) | 2002-12-18 |
| BG101846A (en) | 1998-07-31 |
| PL321890A1 (en) | 1997-12-22 |
| CA2210871C (en) | 2009-04-07 |
| DE69529235T2 (de) | 2003-09-04 |
| NO326612B1 (no) | 2009-01-19 |
| HU223272B1 (hu) | 2004-04-28 |
| AU720635B2 (en) | 2000-06-08 |
| UA66749C2 (en) | 2004-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ284846A (en) | 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof | |
| IL152659A (en) | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer | |
| ES2124203T1 (es) | Inhibidores de elastasa de neutrofilos humanos y catepsina g humana. | |
| GEP20022788B (en) | Pharmaceutical Compositions Having Appetite Suppressant Activity | |
| PT910647E (pt) | Variantes hiperactivas da dnase i humana | |
| ATE67505T1 (de) | Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. | |
| HUP9901144A2 (hu) | Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények | |
| BR9807076B1 (pt) | "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica" | |
| FI972308A (fi) | 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
| HUP9602498A2 (hu) | Antimikrobiális hatású gyógyászati készítmények | |
| SI9520153B (sl) | Variante humane DNaze I | |
| HRP20030215B1 (en) | Chemokine mutants in the tratment of multiple sclerosis | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine | |
| ATE311897T1 (de) | Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| BG101847A (en) | Human dnase i variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date |